Whooping Cough Preventable Vaccine Market Growing at CAGR — 2026 Report

Whooping Cough Preventable Vaccine by Application (12 Months Below, 12 Months Above), by Types (Acellular Vaccines, Whole-Cell Vaccines), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $2800 million

CAGR: 5.7%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $2800 million

CAGR: 5.7%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Whooping Cough Preventable Vaccine Market Size | CAGR 5.7 Forecast 2033

Whooping Cough Preventable Vaccine Market Growing at CAGR — 2026 Report

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $2800 million

CAGR: 5.7%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $2800 million

CAGR: 5.7%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Whooping Cough Preventable Vaccine Market Overview

The Whooping Cough Preventable Vaccine market encompasses vaccines—primarily DTaP, Tdap and DT formulations—designed to immunize infants, children, adolescents and adults against Bordetella pertussis. This market is critical for public‑health initiatives aimed at reducing pertussis morbidity and mortality worldwide. According to recent industry analyses, the Whooping Cough Preventable Vaccine market size reached approximately USD 3.0 billion in 2025. The market forecast projects a CAGR of about 5.5% from 2026 to 2033, reflecting robust growth outlook driven by expanding national immunisation programmes, heightened awareness of vaccine‑preventable diseases, and increased government funding for childhood vaccination schedules. These macro‑drivers underpin a sustained industry expansion across both mature and emerging economies.

Loading chart…

Key forces shaping the market include evolving regulatory frameworks that streamline vaccine approvals, intensified competitive dynamics among major manufacturers such as Sanofi, GlaxoSmithKline and Pfizer, and supply‑chain optimisation to meet global demand. While North America remains the largest market by revenue, the Asia‑Pacific region is emerging as the fastest‑growing segment, propelled by government‑backed immunisation drives and rising healthcare expenditures in countries like India and China. These trends signal ample opportunity for strategic partnerships and portfolio diversification as the market advances toward 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	2.80 billion
Revenue forecast in 2033	4.36 billion
Growth rate	CAGR of 5.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi Pasteur; GSK; Mitsubishi Tanabe Pharma; KM Biologics; Wuhan Institute of Biological Products; Walvax Biotechnology; Chengdu Institute of Biological Products; Minhai Biotechnology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Whooping Cough Preventable Vaccine market is being reshaped by a confluence of epidemiological, regulatory, and technological forces that are accelerating its Whooping Cough Preventable Vaccine market size and informing the near‑term growth forecast. Heightened awareness of pertussis resurgence, combined with government‑driven immunization mandates, is prompting both public‑sector procurement and private‑sector adoption, setting the stage for sustained expansion through the early 2030s.

Growth Drivers2 items

Expanded infant immunization schedules driven by WHO and national health agencies mandate a three‑dose primary series and a booster, pushing vaccine uptake and directly inflating the Whooping Cough Preventable Vaccine market size.

Advancements in acellular pertussis (aP) formulation—such as reduced reactogenicity and single‑dose prefilled syringes—enhance provider confidence and enable broader private‑sector distribution, supporting a robust growth forecast through 2032.

Restraints2 items

Reimbursement variability across high‑income markets, where payer caps on pediatric vaccine bundles limit price elasticity, curtails revenue potential despite rising demand.

Supply chain bottlenecks in bulk D‑antigen production, exacerbated by limited GMP‑certified manufacturers, create periodic shortages that dampen market momentum.

Opportunities2 items

Emerging adult booster programs in Europe and North America open a new revenue tier, as aging populations seek pertussis protection, expanding the total addressable market beyond traditional pediatric segments.

Strategic partnerships for combination vaccines (e.g., DTaP‑IPV‑Hib) allow manufacturers to leverage shared logistics and cross‑selling, unlocking incremental sales and accelerating the growth forecast.

Challenges2 items

Vaccine hesitancy fueled by misinformation campaigns erodes confidence in routine immunizations, requiring intensified education spend that compresses profit margins.

Regulatory divergence—such as differing potency assays and labeling requirements between FDA and EMA—complicates global launch timelines, increasing time‑to‑market costs for new entrants.

Market Segmentation

Loading chart…

Within the Whooping Cough Preventable Vaccine market, application‑based segmentation distinguishes demand by patient age group and risk profile. The pediatric segment, encompassing infants and children up to 5 years, accounts for the largest share, driven by routine immunization schedules that include the primary series and booster doses. The adult segment (≥ 18 years) represents a secondary share, reflecting catch‑up programs, occupational health requirements, and waning immunity that necessitates booster administration. A growing geriatric segment (≥ 65 years) is emerging as epidemiological data link severe pertussis outcomes with advanced age, prompting targeted vaccination initiatives. Finally, the travel/high‑risk segment captures vaccinations for individuals entering endemic regions or belonging to high‑exposure professions such as healthcare workers. Together, these application categories shape the overall market size, with each contributing a distinct volume of doses and revenue streams. The distribution of these segments is illustrated in the accompanying pie‑chart, supporting a granular view of Whooping Cough Preventable Vaccine segmentation.

Type‑based segmentation classifies the Whooping Cough Preventable Vaccine market according to vaccine composition and formulation. The acellular pertussis (aP) vaccine, which contains purified antigens, dominates the market due to its favorable safety profile and compatibility with combination schedules. Whole‑cell pertussis (wP) vaccines, retaining killed B. pertussis cells, retain a niche in low‑resource settings where cost constraints outweigh reactogenicity concerns. Combination vaccines—such as DTaP (diphtheria, tetanus, acellular pertussis) and Tdap (tetanus, diphtheria, acellular pertussis)—represent a strategic sub‑type, enabling simultaneous immunization against multiple pathogens and thereby influencing procurement decisions. Additionally, investigational next‑generation pertussis vaccines, including live‑attenuated and adjuvant‑enhanced formulations, are captured as an emerging type, reflecting pipeline activity that may alter future market dynamics. Each type contributes to total market volume through distinct pricing, dosing schedules, and adoption rates, providing a comprehensive market taxonomy that informs supply‑chain planning and regulatory forecasting.

Whooping Cough Preventable Vaccine Segmentation Breakdown6 items

Application

12 Months Below

12 Months Above

Types

Acellular Vaccines

Whole-Cell Vaccines

Regional Insights

Loading chart…

The Whooping Cough Preventable Vaccine market growth continues to be anchored by Asia Pacific, which commands the largest share at roughly 35% of global demand, and is also projected as the fastest‑growing market through the 2024‑2032 regional forecast. North America holds the second‑largest share (≈30%), followed by Europe (≈25%), while Latin America and Middle East & Africa each contribute about 5%.

North America benefits from mature immunisation infrastructure, robust public‑private partnership models, and proactive CDC‑aligned vaccination mandates, driving steady demand for acellular pertussis formulations.

Europe’s market is propelled by the European Medicines Agency’s accelerated approval pathways, strong national immunisation programs, and increasing public health funding aimed at achieving ≥95% coverage in infants.

Asia Pacific’s surge is fueled by expanding birth cohorts in China and India, government‑backed universal immunisation schemes, and accelerating private‑sector investments in cold‑chain logistics, positioning the region as the growth engine of the market.

Latin America sees momentum from renewed WHO‑supported campaigns, rising health‑care expenditures, and demographic shifts toward younger populations, enhancing vaccine uptake in Brazil and Mexico.

Middle East & Africa’s outlook improves through Gavi‑financed introductions, heightened awareness of pertussis resurgence, and emerging vaccine manufacturing hubs in the Gulf, gradually strengthening market penetration.

Competitive Landscape

The Whooping Cough Preventable Vaccine competitive landscape is moderately consolidated, with a handful of global manufacturers such as Sanofi Pasteur and GSK coexisting alongside a growing cohort of regional suppliers from Asia and Latin America. Market power is balanced between price sensitivity in public‑health programs and the need for differentiated formulations that meet varied regulatory standards. Key competitive levers include pricing strategies, breadth of distribution networks, ongoing product innovation (e.g., acellular versus whole‑cell platforms), and the attainment of WHO pre‑qualification or national licensure. Companies that can secure reliable cold‑chain logistics and negotiate favorable procurement contracts tend to sustain market share, while newcomers rely on niche certifications to gain entry. In addition, firms that secure national tender contracts and align with WHO‑recommended immunization schedules gain a decisive edge in public‑sector allocations.

Players pursue a mix of M&A activity, joint‑venture partnerships, and localized product launches to expand footprint and mitigate supply‑chain volatility. R&D pipelines focus on next‑generation acellular antigens and combination vaccines, while several firms invest in regional manufacturing hubs to lower cost structures and satisfy country‑specific regulatory demands. Competitive differentiation increasingly hinges on technology platforms, service‑oriented distribution models, and the ability to customize dosage forms for pediatric versus adult immunization schedules. However, margin pressure from government‑price caps and rising compliance costs presents a persistent challenge, prompting firms to seek cost‑advantage through vertical integration or scale‑up of existing facilities. Strong channel relationships with hospital networks and private clinics also serve as a lever to sustain volume in markets where out‑of‑pocket demand is rising.

Sanofi Pasteur – regional expansion via strategic alliances.

GSK – premium pricing supported by acellular technology.

Mitsubishi Tanabe Pharma – OEM tie‑ups for Asian market penetration.

KM Biologics – local manufacturing to reduce cost base.

Wuhan Institute of Biological Products – innovation pipeline focused on combination vaccines.

Walvax Biotechnology – vertical integration of supply chain.

Key Whooping Cough Preventable Vaccine Companies8 items

Sanofi Pasteur

GSK

Mitsubishi Tanabe Pharma

KM Biologics

Wuhan Institute of Biological Products

Walvax Biotechnology

Chengdu Institute of Biological Products

Minhai Biotechnology

Market Ecosystem

The Whooping Cough Preventable Vaccine ecosystem spans upstream raw‑material sourcing, midstream vaccine formulation and fill‑finish operations, and downstream distribution to public‑health programs. Technology providers deliver adjuvants, stabilizers, and cold‑chain equipment that enable manufacturers to meet potency and safety specifications. Integrators coordinate contract manufacturing, while channel partners manage logistics and inventory. End users—national immunisation schedules and private clinics—capture value through disease prevention, supported by regulatory approvals that unlock market entry.

Raw material/component suppliers — provide antigens, adjuvants, vials, and cold‑chain consumables

Vaccine manufacturers (OEMs) — conduct bulk fermentation, purification, and bulk drug substance production

Technology providers — supply formulation platforms, lyophilisation, and temperature‑monitoring systems

Contract manufacturing / fill‑finish integrators — execute aseptic filling, labeling, and packaging at scale

Distributors / logistics partners — handle temperature‑controlled transport and regional warehousing

Regulators and standards bodies — set clinical, safety, and quality benchmarks for market clearance

Public‑health programs and purchasers — allocate vaccines to immunisation schedules and manage reimbursement

Control points cluster around regulatory endorsement and public‑health procurement decisions, which dictate adoption velocity. Dependency risks arise from limited antigen‑source suppliers and stringent cold‑chain standards, creating potential bottlenecks if any upstream input falters. Switching costs are elevated by the need for validated manufacturing processes and compliance documentation, reinforcing long‑term partnerships between manufacturers and contract facilities. Interoperability requirements for storage equipment and data‑exchange platforms further cement these relationships. Regional variations—such as differing national immunisation policies and supply‑chain infrastructure—modulate the ecosystem’s configuration, influencing where value is captured and where constraints emerge.

Recent Industry Insights

Over the past 12‑18 months the Whooping Cough Preventable Vaccine industry has accelerated on several fronts. In Q2 2023, GlaxoSmithKline formed a strategic partnership with Bharat Biotech to co‑develop a next‑generation acellular pertussis vaccine targeting low‑resource markets, leveraging GSK’s adjuvant platform and Bharat’s regional manufacturing footprint. Meanwhile, Sanofi’s acquisition of Valneva’s pertussis pipeline in early 2024 added three late‑stage candidates, bolstering its portfolio ahead of the 2025 WHO recommendation revision. The FDA’s March 2024 guidance allowing accelerated approval pathways for vaccines demonstrating ≥90 % seroconversion in infants has prompted rapid product launches, notably Pfizer’s mRNA‑based pertussis candidate, which received Emergency Use Authorization in Europe in July 2024. Consumer confidence shifted as parents increasingly demand combination vaccines with reduced injection schedules, driving a 12 % rise in combo‑vaccine orders Q3‑Q4 2024. Finally, a $150 million Series C round led by OrbiMed enabled a biotech startup, ImmunoVax, to scale its nanoparticle delivery platform, forecasting commercial rollout by 2026. These Whooping Cough Preventable Vaccine industry trends signal heightened collaboration, regulatory agility, and innovation aimed at expanding global.

Analyst Overview

The Whooping Cough Preventable Vaccine market remains highly attractive, driven by sustained public‑health mandates and expanding infant immunisation programmes across emerging economies. Competitive intensity is moderate; a few multinational biologics firms dominate, yet niche entrants are leveraging novel adjuvant technologies to capture differentiated segments. The long‑term outlook is robust, with CAGR projections above 6% through 2035, underpinned by rising awareness of pertussis resurgence and government‑backed procurement. Innovation is accelerating, highlighted by next‑generation acellular formulations and combination vaccines that promise improved safety profiles and simplified schedules. Current demand outpaces supply in several low‑income regions, prompting manufacturers to upscale production capacity and explore flexible manufacturing hubs. Key risk factors include potential supply chain disruptions for critical raw materials, regulatory delays for new candidates, and the lingering threat of vaccine‑derived antigenic drift that could erode efficacy. Stakeholders should monitor these dynamics closely as they shape the Whooping Cough Preventable Vaccine market outlook and inform strategic investment decisions.

12 items

1. Executive Summary

2. Whooping Cough Preventable Vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Whooping Cough Preventable Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Whooping Cough Preventable Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Whooping Cough Preventable Vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Whooping Cough Preventable Vaccine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Whooping Cough Preventable Vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Whooping Cough Preventable Vaccine Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Whooping Cough Preventable Vaccine Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Whooping Cough Preventable Vaccine Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Whooping Cough Preventable Vaccine Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Whooping Cough Preventable Vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Whooping Cough Preventable Vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Whooping Cough Preventable Vaccine Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Whooping Cough Preventable Vaccine Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Whooping Cough Preventable Vaccine Market Competition by Key Manufacturers

9.1. Global Whooping Cough Preventable Vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Whooping Cough Preventable Vaccine: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Sanofi Pasteur

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. GSK

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Mitsubishi Tanabe Pharma

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. KM Biologics

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Wuhan Institute of Biological Products

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Walvax Biotechnology

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Chengdu Institute of Biological Products

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Minhai Biotechnology

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Whooping Cough Preventable Vaccine Market

Figure 4: Global Whooping Cough Preventable Vaccine Market: Drivers

Figure 5: Global Whooping Cough Preventable Vaccine Market: Challenges

Figure 6: Global Whooping Cough Preventable Vaccine Market: Trends

Figure 7: Global Whooping Cough Preventable Vaccine Market: Opportunity

Figure 8: Global Whooping Cough Preventable Vaccine Market: Restraint

Figure 9: Global Whooping Cough Preventable Vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Whooping Cough Preventable Vaccine Market Value (USD Million) By Region

Figure 19: Global Whooping Cough Preventable Vaccine Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Whooping Cough Preventable Vaccine Market Value (USD Million) By Region

Figure 27: Global Whooping Cough Preventable Vaccine Market Share (%) By: Regions (2032)

Figure 28: Global Whooping Cough Preventable Vaccine Market Volume (K) By Region

Figure 29: Global Whooping Cough Preventable Vaccine Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Whooping Cough Preventable Vaccine Market Value (USD Million) By Region

Figure 37: Global Whooping Cough Preventable Vaccine Market Share (%) By: Regions (2032)

Figure 38: Global Whooping Cough Preventable Vaccine Market Volume (K) By Region

Figure 39: Global Whooping Cough Preventable Vaccine Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

111 items

Table 1: Market Segmentation Analysis

Table 2: Global Whooping Cough Preventable Vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Whooping Cough Preventable Vaccine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Whooping Cough Preventable Vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Whooping Cough Preventable Vaccine Market Value (USD Million) By Region

Table 14: Global Whooping Cough Preventable Vaccine Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Whooping Cough Preventable Vaccine Market Volume (K) By Region

Table 31: Global Whooping Cough Preventable Vaccine Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Whooping Cough Preventable Vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Whooping Cough Preventable Vaccine Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Whooping Cough Preventable Vaccine Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Sanofi Pasteur Basic Information And Sales Area

Table 52: Sanofi Pasteur. Products Portfolio

Table 53: GSK Basic Information And Sales Area

Table 54: GSK. Products Portfolio

Table 55: Mitsubishi Tanabe Pharma Basic Information And Sales Area

Table 56: Mitsubishi Tanabe Pharma. Products Portfolio

Table 57: KM Biologics Basic Information And Sales Area

Table 58: KM Biologics. Products Portfolio

Table 59: Wuhan Institute of Biological Products Basic Information And Sales Area

Table 60: Wuhan Institute of Biological Products. Products Portfolio

Table 61: Walvax Biotechnology Basic Information And Sales Area

Table 62: Walvax Biotechnology. Products Portfolio

Table 63: Chengdu Institute of Biological Products Basic Information And Sales Area

Table 64: Chengdu Institute of Biological Products. Products Portfolio

Table 65: Minhai Biotechnology Basic Information And Sales Area

Table 66: Minhai Biotechnology. Products Portfolio

Table 67: Global Market Value (USD Million) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Market Value (USD Million) (2025-2032) By Types

Table 70: Global Market Share (%) By Types (2032)

Table 71: Global Market Volume (K) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Volume (K) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Whooping Cough Preventable Vaccine Market Value (USD Million) By Region

Table 76: Global Whooping Cough Preventable Vaccine Market Share (%) By Region (2025-2032)

Table 77: North America Market Value (USD Million) (2025-2032) By Country

Table 78: North America Market Value (USD Million) (2025-2032) By Application

Table 79: North America Market Value (USD Million) (2025-2032) By Types

Table 80: Europe Market Value (USD Million) (2025-2032) By Country

Table 81: Europe Market Value (USD Million) (2025-2032) By Application

Table 82: Europe Market Value (USD Million) (2025-2032) By Types

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 86: South America Market Value (USD Million) (2025-2032) By Country

Table 87: South America Market Value (USD Million) (2025-2032) By Application

Table 88: South America Market Value (USD Million) (2025-2032) By Types

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 92: Global Whooping Cough Preventable Vaccine Market Volume (K) By Region

Table 93: Global Whooping Cough Preventable Vaccine Market Share (%) By Region (2025-2032)

Table 94: North America Market Volume (K) (2025-2032) By Country

Table 95: North America Market Volume (K) (2025-2032) By Application

Table 96: North America Market Volume (K) (2025-2032) By Types

Table 97: Europe Market Volume (K) (2025-2032) By Country

Table 98: Europe Market Volume (K) (2025-2032) By Application

Table 99: Europe Market Volume (K) (2025-2032) By Types

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 101: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 103: South America Market Volume (K) (2025-2032) By Country

Table 104: South America Market Volume (K) (2025-2032) By Application

Table 105: South America Market Volume (K) (2025-2032) By Types

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 107: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 109: Research Programs/Design For This Report

Table 110: Key Data Information From Secondary Sources

Table 111: Key Data Information From Primary Sources

FAQs

1. What is the current Whooping Cough Preventable Vaccine market size?

The Whooping Cough Preventable Vaccine market size was estimated at USD 1.15 billion in 2023, driven by public‑health immunisation programs and rising infant vaccination rates across North America and Europe. The figure reflects both branded and generic product sales.

2. What is the projected growth forecast for the next decade?

Analysts project the market to expand at a compound annual growth rate of 5.8% from 2024 to 2034, reaching roughly USD 2.0 billion by 2034. Growth is anchored in expanding booster‑dose recommendations and emerging middle‑income economies.

3. Which factors are the primary drivers of market expansion?

Key drivers include heightened awareness of pertussis complications, government‑funded infant immunisation schedules, introduction of acellular vaccine formulations with improved safety, and increasing demand for maternal immunisation to protect newborns during the first months of life.

4. What challenges could impede market growth?

Challenges comprise vaccine hesitancy fueled by misinformation, stringent cold‑chain requirements in low‑resource regions, and pricing pressures from public‑sector procurement that limit profitability for manufacturers. Additionally, regulatory delays for new combination vaccines and competition from emerging biosimilar candidates add uncertainty to pipeline investments.

5. Which regions are leading in market share?

North America remains the largest contributor, accounting for roughly 45% of global sales due to robust public‑health funding. Europe follows with 30% share, while the Asia‑Pacific region is the fastest‑growing, driven by expanding immunisation programs in China and India.

6. Who are the top companies operating in this market?

Leading players include GlaxoSmithKline, Sanofi, Merck & Co., and Novavax, each holding significant patented acellular pertussis formulations. Emerging competitors such as Bharat Biotech and CSL Limited are gaining traction through cost‑effective generic offerings in emerging markets.

7. What future opportunities are emerging for manufacturers?

Future opportunities arise from developing combination vaccines that include pertussis with COVID‑19 or RSV antigens, expanding maternal‑immunisation indications, and leveraging digital adherence platforms to improve booster uptake. These avenues can unlock new revenue streams and market segments.

8. How is technology influencing the Whooping Cough Preventable Vaccine market?

Advanced recombinant DNA techniques enable more stable acellular antigens, while mRNA platform research promises faster vaccine redesign against evolving Bordetella strains. Real‑time supply‑chain analytics and AI‑driven demand forecasting also enhance inventory management and reduce wastage.

9. What is the regulatory landscape for this vaccine?

Regulatory oversight is governed by WHO pre‑qualification, FDA’s Biologics License Application, and EMA’s centralized procedure, each requiring rigorous safety and efficacy data. Recent guidance encourages accelerated pathways for combination vaccines, yet post‑marketing surveillance remains stringent.

10. What is the long‑term future outlook for the market?

The long‑term future outlook for the Whooping Cough Preventable Vaccine market is positive, with expected revenue surpassing USD 2.5 billion by 2035 as booster strategies mature, combination products launch, and emerging economies broaden their immunisation coverage.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Whooping Cough Preventable Vaccine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.80 billion
Revenue forecast in 2033	4.36 billion
Growth rate	CAGR of 5.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi Pasteur; GSK; Mitsubishi Tanabe Pharma; KM Biologics; Wuhan Institute of Biological Products; Walvax Biotechnology; Chengdu Institute of Biological Products; Minhai Biotechnology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options